|国家科技期刊平台
首页|期刊导航|中国药物经济学|半夏泻心汤治疗新型冠状病毒感染后失眠的疗效

半夏泻心汤治疗新型冠状病毒感染后失眠的疗效OA

Therapeutic Effect of Banxia Xiexin Decoction on Insomnia after Corona Virus Disease 2019

中文摘要英文摘要

目的 探讨半夏泻心汤治疗新型冠状病毒感染后失眠的疗效.方法 采用随机数字表法将南京中医药大学附属苏州市中医医院2023 年1-6 月收治的新型冠状病毒感染后失眠患者120 例分为试验组和对照组,各60 例.对照组予以艾司唑仑治疗,试验组加用半夏泻心汤治疗,两组均治疗4 周.比较两组治疗后临床疗效,治疗前后睡眠质量、中医证候积分、抑郁评分、5-羟色胺(5-HT)水平.结果 试验组治疗有效率高于对照组(P<0.05);治疗后两组匹茨堡睡眠质量指数(PSQI)评分、中医证候积分、17 项版汉密尔顿抑郁量表(HAMD-17)评分均降低(P<0.05),且试验组均低于对照组(P<0.05);治疗后两组5-HT水平升高(P<0.05),且试验组高于对照组(P<0.05).结论 半夏泻心汤治疗新型冠状病毒感染后失眠可提高治疗效果,改善睡眠质量、中医证候、抑郁情绪,降低5-HT水平.

[Abstrcat]Objective To explore the therapeutic effect of Banxia Xiexin Decoction on insomnia after corona virus disease 2019.Methods A total of 120 patients with insomnia after corona virus disease 2019 admitted to Suzhou Hospital of Traditional Chinese Medicine Affiliated to Nanjing University of Chinese Medicine from January 2023 to June 2023 were divided into experimental group and control group,with 60 cases in each group.The control group was treated with Esazolam,the experimental group was treated with Banxia Xiexin decoction,both groups were treated for 4 weeks.The clinical efficacy,sleep quality,TCM syndrome score,depression score and 5-hydroxytryptamine(5-HT)level before and after treatment were compared between the two groups.Results The effective rate of experimental group was higher than that of control group(P<0.05).After treatment,PSQI scores,TCM syndrome scores,17-item Hamilton Depression Scale(HAMD-17)scores of both groups were decreased(P<0.05),and the test group were lower than the control group(P<0.05).After treatment,the level of 5-HT in the experimental group was higher han that in the control group(P<0.05).Conclusion Banxia Xiexin Decoction can improve the therapeutic effect of insomnia after novel coronavirus infection,improve sleep quality,traditional Chinese medicine syndrome,depression,and reduce 5-HT level.

李琰;钱惠峰

南京中医药大学附属苏州市中医医院脑病科,南京 215000

中医学

新型冠状病毒感染失眠不寐半夏泻心汤

Corona virus disease 2019InsomniaBumeiBanxia Xiexin Decoction

《中国药物经济学》 2024 (007)

44-47,52 / 5

苏州市科教兴卫项目(NKJ180126)

10.12010/j.issn.1673-5846.2024.07.008

评论